Mucin-producing tumors and tumor-like lesions involving the prostate: A comprehensive review

Advances in Anatomic Pathology

Volumn 19, Issue 6, 2012, Pages 374-387

  Bohman, Keith D ^a   Osunkoya, Adeboye O ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Adenocarcinoma; Colloid; Immunohistochemistry; Mucinous; Prognosis; Prostate

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

BLADDER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MUCIN PRODUCING PROSTATE TUMOR; MUCINOUS PROSTATIC ADENOCARCINOMA; PRIMARY MUCIN PRODUCING UROTHELIAL TYPE PROSTATE ADENOCARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE TUMOR; REVIEW; SIGNET RING CARCINOMA; TUMOR DIFFERENTIATION; URETHRITIS;

ADENOCARCINOMA, MUCINOUS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MUCINS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867971548     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318271a361     Document Type: Review

References (148)

1. Cricco RP, Kassis J. Mucinous adenocarcinoma of prostate. Urology. 1979;14:276-278.
2. Elbadawi A, Craig W, Linke CA, et al. Prostatic mucinous carcinoma. Urology. 1979;13:658-666.
3. Furuta A, Naruoka T, Hasegawa N, et al. Mucinous adenocarcinoma of the prostate: a case report and review of 32 cases on immunohistochemical study of both PSA and CEA. Nihon Hinyokika Gakkai Zasshi. 2003;94:570-573.
4. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol. 2004;17:316-327.
5. Hsueh Y, Tsung SH. Prostatic mucinous adenocarcinoma. Urology. 1984;24:626-627.
6. Nagakura K, Hayakawa M, Mukai K, et al. Mucinous adenocarcinoma of prostate: a case report and review of the literature. J Urol. 1986;135:1025-1028.
7. Navas Pastor J, Mun oz Vicente E, García Ligero J, et al. Prostatic mucinous adenocarcinoma. Report of a new case and review of the literature. Arch Esp Urol. 2001;54:820-822.
8. Noma M, Mori N, Kobayashi Y, et al. A case report: mucinous carcinoma of prostate. Hinyokika Kiyo. 2003;49: 591-593.
9. Olivas TP, Brady TW. Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival. Urology. 1996;47:256-258.
10. Osunkoya AO, Adsay NV, Cohen C, et al. MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy. Mod Pathol. 2008;21:789-794.
11. Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol. 2008; 32:468-472.
12. Ro JY, Grignon DJ, Ayala AG, et al. Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol. 1990;21:593-600.
13. Tran TA, Jennings TA, Ross JS, et al. Pseudomyxoma ovarii like Post therapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy. Am J Surg Pathol. 1998;22: 347-354.
14. Uchijima Y, Ito H, Takahashi M, et al. Prostate mucinous adenocarcinoma with signet ring cell. Urology. 1990;36: 267-268.
15. Uyama T, Uchijima Y, Ito H, et al. Prostate mucinous adenocarcinoma with signet ring cell. Urology. 1990;36: 267-268.
16. Rhee AC, Olgac S, Ohori M, et al. Mucinous adenocarcinoma of the prostate: a case report of long-term disease-free survival and a review of the literature. Urology. 2004;63: 779-780.
17. Saito S, Iwaki H. Mucin-producing carcinoma of the prostate: review of 88 cases. Urology. 1999;54:141-144.
18. Lane BR, Magi-Galluzzi C, Reuther AM, et al. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;68:825-830.
19. Xie LP, Qin J, Zheng XY, et al. Age and pathological features of 481 prostate cancer patients. Zhonghua Nan Ke Xue. 2005;11:428-430.
20. Epstein JI, Lieberman PH. Mucinous adenocarcinoma of the prostate gland. Am J Surg Pathol. 1985;9:299-308.
21. McNeal JE, Alroy J, Villers A, et al. Mucinous differentiation in prostatic adenocarcinoma. Hum Pathol. 1991;22:979-988.
22. Boyd S. A case of colloid scirrhus of the prostate. Trans Pathol Soc Lond. 1882;33:200-203.
23. Watarai Y, Demura T, Togashi M, et al. Mucinous adenocarcinoma of the prostate. A case report and analysis of the literature. Nihon Hinyokika Gakkai Zasshi. 1994;85: 1276-1279.
24. de Diego Rodríguez E, Martín García B, Herná ndez Rodríguez R, et al. Mucinous adenocarcinoma of the prostate. Report of a new case. Arch Esp Urol. 2001;54: 256-260.
25. Efros MD, Fischer J, Mallouh C, et al. Unusual primary prostatic malignancies. Urology. 1992;39:407-410.
26. Thompson GJ, Albers DD, Broders AC. Unusual carcinomas involving the prostate gland. J Urol. 1953;69:416-425.
27. Ishizu K, Yoshihiro S, Joko K, et al. Mucinous adenocarcinoma of the prostate with good response to hormonal therapy: a case report. Hinyokika Kiyo. 1991;37: 1057-1060.
28. Klissurow A. Carcinoma gelatinosum prostate. Virchows Arch. 1928;268:515.
29. Bukovics C. Colloid cancer of the prostate. Krebsarzt. 1947;2:167-172.
30. Skodras G, Wang J, Kragel PJ. Primary prostatic signet-ring cell carcinoma. Urology. 1993;42:338-342.
31. Chica G, Johnson DE, Ayala AG. Mucinous adenocarcinoma of the prostate. J Urol. 1977;118:124-125.
32. Gumus E, Yilmaz B, Miroglu C. Prostate mucinous adenocarcinoma with signet ring cell. Int J Urol. 2003;10: 239-241.
33. Manne RK, Haddad FS. Mucinous adenocarcinoma of prostate. Urology. 1989;33:247-249.
34. Patel RC, Dias R, Fernandes M, et al. Adenocarcinoma of the prostate; mucin secreting. N Y State J Med. 1981;81: 936-937.
35. Franks LM, O'shea JD, Thomson AE. Mucin in the prostate: a histochemical study in normal glands, latent, clinical, and colloid cancers. Cancer. 1964;17:983-991.
36. Ishibashi Y, Kishida T, Yamaguchi T, et al. Two cases of mucinous adenocarcinoma of the prostate. Hinyokika Kiyo. 1992;38:463-467.
37. Ló pez-Navarro N, Ló pez-Sá nchez JC, Pérez-Enríquez JE, et al. Atypical skin metastases of mucinous adenocarcinoma of the prostate with signet ring cells. Actas Dermosifiliogr. 2009;100:338-341.
38. Lee DW, Ro JY, Sahin AA, et al. Mucinous adenocarcinoma of the prostate with endobronchial metastasis. Am J Clin Pathol. 1990;94:641-645.
39. Ashburn L. New bone formation in a primary carcinoma of the prostate gland. Arch Pathol. 1939;28:145.
40. Larrousse C, Brasseur P, Sukkarieh F. Port-site metastasis following laparoscopic radical prostatectomy for mucinous adenocarcinoma of the prostate. J Radiol. 2005;86:337-339.
41. Medina Pérez M, Valero Puerta JA, Valpuesta Ferná ndez I, et al. Mucinous adenocarcinoma of the prostate. Arch Esp Urol. 2001;54:253-254.
42. Rodríguez Ferná ndez A, García Gonzá lez A, Bengoechea Miranda O, et al. Mucinous adenocarcinoma of the prostatic gland. Histochemical and immunohistochemical studies. Arch Esp Urol. 1992;45:572-575.
43. Outwater E, Schiebler ML, Tomaszewski JE, et al. Mucinous carcinomas involving the prostate: atypical findings at MR imaging. J Magn Reson Imaging. 1992;2:597-600.
44. Westphalen AC, Coakley FV, Kurhanewicz J, et al. Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features. Am J Roentgenol. 2009;193:238-243.
45. Grignon DJ, O'Malley FP. Mucinous metaplasia in the prostate gland. Am J Surg Pathol. 1993;17:287-290.
46. Pinder SE, McMahon RF. Mucins in prostatic carcinoma. Histopathology. 1990;16:43-46.
47. Noiwan S, Rattanarapee S. Mucin production in prostatic adenocarcinoma: a retrospective study of 190 radical prostatectomy and/or core biopsy specimens in department of pathology, Siriraj Hospital, Mahidol University, Thailand. J Med Assoc Thai. 2011;94:224-230.
48. Taylor NS. Histochemistry in the diagnosis of early prostatic carcinoma. Hum Pathol. 1979;10:513-520.
49. Ro JY, el-Naggar A, Ayala AG, et al. Signet-ring-cell carcinoma of the prostate. Electron-microscopic and immunohistochemical studies of eight cases. Am J Surg Pathol. 1988;12:453-460.
50. Tran KP, Epstein JI. Mucinous adenocarcinoma of urinary bladder type arising from the prostatic urethra. Distinction from mucinous adenocarcinoma of the prostate. Am J Surg Pathol. 1996;20:1346-1350.
51. Alline KM, Cohen MB. Signet-ring cell carcinoma of the prostate. Arch Pathol Lab Med. 1992;116:99-102.
52. Hejka AG, England DM. Signet ring cell carcinoma of prostate. Immunohistochemical and ultrastructural study of a case. Urology. 1989;34:155-158.
53. Kuroda N, Yamasaki I, Nakayama H, et al. Prostatic signetring cell carcinoma: case report and literature review. Pathol Int. 1999;49:457-461.
54. Remmele W, Weber A, Harding P. Primary signet-ring cell carcinoma of the prostate. Hum Pathol. 1988;19:478-480.
55. Sá ez C, Japó n MA, Conde AF, et al. Sialomucins are characteristically O-acylated in poorly differentiated and colloid prostatic adenocarcinomas. Mod Pathol. 1998;11: 1193-1197.
56. Sá ez C, Japó n MA, Poveda MA, et al. Mucinous (colloid) adenocarcinomas secrete distinct O-acylated forms of sialomucins: a histochemical study of gastric, colorectal and breast adenocarcinomas. Histopathology. 2001;39:554-560.
57. Epstein JI, Fynheer J. Acidic mucin in the prostate: can it differentiate adenosis from adenocarcinoma? Hum Pathol. 1992;23:1321-1325.
58. Gal R, Koren R, Nofech-Mozes S, et al. Evaluation of mucinous metaplasia of the prostate gland by mucin histochemistry. Br J Urol. 1996;77:113-117.
59. Ro JY, Grignon DJ, Troncoso P, et al. Mucin in prostatic adenocarcinoma. Semin Diagn Pathol. 1988;5:273-283.
60. Sousa Escandó n A, Argü elles Pintos M, Picallo Sá nchez J, et al. Mucinous carcinoma of the prostate: critical review of Elbadawi's criteria. Actas Urol Esp. 2000;24:155-162.
61. Dhom G. Unusual prostatic carcinomas. Pathol Res Pract. 1990;186:28-36.
62. Epstein JI, Allsbrook WC Jr, Amin MB, et al. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29: 1228-1242.
63. Arangelovich V, Tretiakova M, SenGupta E, et al. Pathogenesis and significance of collagenous micronodules of the prostate. Appl Immunohistochem Mol Morphol. 2003;11: 15-19.
64. Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia, and glomerulations: diagnostic features of limited cancer on prostate needle biopsy. Am J Surg Pathol. 1999;23:918-924.
65. Bostwick DG, Wollan P, Adlakha K. Collagenous micronodules in prostate cancer. A specific but infrequent diagnostic finding. Arch Pathol Lab Med. 1995;119:444-447.
66. Varma M, Lee MW, Tamboli P, et al. Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. A study of 250 consecutive cases in a routine surgical pathology practice. Arch Pathol Lab Med. 2002;126:554-561.
67. Thorson P, Vollmer RT, Arcangeli C, et al. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod Pathol. 1998;11:543-551.
68. Feiner HD, Gonzalez R. Carcinoma of the prostate with atypical immunohistological features. Clinical and histologic correlates. Am J Surg Pathol. 1986;10:765-770.
69. Stein BS, Vangore S, Petersen RO. Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Urology. 1984;24:146-152.
70. Stein BS, Vangore S, Petersen RO, et al. Immunoperoxidase localization of prostate-specific antigen. Am J Surg Pathol. 1982;6:553-557.
71. Huang Q, Chu PG, Lau SK, et al. Urothelial carcinoma of the urinary bladder with a component of acinar/tubular type differentiation simulating prostatic adenocarcinoma. Hum Pathol. 2004;35:769-773.
72. Mai KT, Landry DC, Collins JP. Secondary colonic adenocarcinoma of the prostate histologically mimicking prostatic ductal adenocarcinoma. Tumori. 2002;88:341-344.
73. Yamaguchi S, Hashimoto H, Kaneko S, et al. Secondary mucinous adenocarcinoma of the prostate in a patient with ulcerative colitis. Urol Int. 1993;50:231-233.
74. Genega EM, Hutchinson B, Reuter VE, et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
75. Sakamoto N, Ohtsubo S, Iguchi A, et al. Intestinal-type mucinous adenocarcinoma arising from the prostatic duct. Int J Urol. 2005;12:509-512.
76. Heyderman E, Brown BM, Richardson TC. Epithelial markers in prostatic, bladder, and colorectal cancer: an immunoperoxidase study of epithelial membrane antigen, carcinoembryonic antigen, and prostatic acid phosphatase. J Clin Pathol. 1984;37:1363-1369.
77. Heidl G. Demonstration of carcinoembryonic antigen (CEA) by means of the immunoperoxidase technique in paraffinembedded specimens of tumour tissues. Exp Pathol. 1982; 21:79-88.
78. Segawa T, Kakehi Y. Primary signet ring cell adenocarcinoma of the prostate: a case report and literature review. Hinyokika Kiyo. 1993;39:565-568.
79. Adsay NV, Merati K, Nassar H, et al. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol. 2003;27:571-578.
80. Hanski C, Hofmeier M, Schmitt-Grä ff A, et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol. 1997;182:385-391.
81. O'Connell JT, Shao ZM, Drori E, et al. Altered mucin expression is a field change that accompanies mucinous (colloid) breast carcinoma histogenesis. Hum Pathol. 1998;29:1517-1523.
82. Cappello F, Rappa F, David S, et al. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res. 2003;23(2B):1325-1331.
83. Cozzi PJ, Wang J, Delprado W, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis. 2005;22:565-573.
84. Adsay NV, Pierson C, Sarkar F, et al. Colloid (mucinous noncystic) carcinoma of the pancreas. Am J Surg Pathol. 2001;25:26-42.
85. Spicer AP, Rowse GJ, Lidner TK, et al. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem. 1995;270:30093-30101.
86. Braga VM, Pemberton LF, Duhig T, et al. Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development. 1992;115:427-437.
87. Scholfield DP, Simms MS, Bishop MC. MUC1 mucin in urological malignancy. BJU Int. Apr. 2003;91:560-566.
88. Hudson MJ, Stamp GW, Chaudhary KS, et al. Human MUC1 mucin: a potent glandular morphogen. J Pathol. 2001;194:373-383.
89. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta. 1995;1241:407-423.
90. Ligtenberg MJ, Buijs F, Vos HL, et al. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 1992;52: 2318-2324.
91. Hilkens J, Ligtenberg MJ, Vos HL, et al. Cell membraneassociated mucins and their adhesion-modulating property. Trends Biochem Sci. 1992;17:359-363.
92. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol. 1993;151:767-776.
93. Kondo K, Kohno N, Yokoyama A, et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 1998;58:2014-2019.
94. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell. 1996;7:565-577.
95. Agrawal B, Krantz MJ, Reddish MA, et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 1998;4:43-49.
96. Dong Y, Walsh MD, Cummings MC, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol. 1997;183:311-317.
97. Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol. 1998;51:667-671.
98. Jang KT, Chae SW, Sohn JH, et al. Coexpression of MUC1 with p53 or MUC2 correlates with lymph node metastasis in colorectal carcinomas. J Korean Med Sci. 2002;17:29-33.
99. McGuckin MA, Walsh MD, Hohn BG, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol. 1995;26:432-439.
100. Nakamori S, Ota DM, Cleary KR, et al. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology. 1994;106: 353-361.
101. Ohgami A, Tsuda T, Osaki T, et al. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg. 1999;67:810-814.
102. Arai T, Fujita K, Fujime M, et al. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol. 2005;12:654-661.
103. Gunia S, May M, Koch S, et al. MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy. Pathol Oncol Res. 2010; 16:371-375.
104. Kirschenbaum A, Itzkowitz SH, Wang JP, et al. MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol. 1999;3:163-168.
105. Li Y, Cozzi PJ. MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets. 2007;7: 259-271.
106. O'Connor JC, Julian J, Lim SD, et al. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic Dis. 2005;8:36-44.
107. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41: 619-624.
108. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24:3847-3852.
109. Carver BS, Tran J, Chen Z, et al. ETS rearrangements and prostate cancer initiation. Nature. 2009;457:E1YE3.
110. Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol. 2010;23:1325-1333.
111. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERGpositive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228-237.
112. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res. 2008; 14:4719-4725.
113. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA. 2008;105:2105-2110.
114. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8: 497-511.
115. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008;27:5348-5353.
116. King JC, Xu J, Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009;41:524-526.
117. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69: 1400-1406.
118. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 2008;68:73-80.
119. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68:3584-3590.
120. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177-188.
121. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006;66:3396-3400.
122. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648.
123. Zong Y, Xin L, Goldstein AS, et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA. 2009;106:12465-12470.
124. Epstein JI, Kuhajda FP, Lieberman PH. Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum Pathol. 1986;17:939-942.
125. Rodríguez Martínez JJ, Madrigal Rubiales B, Pérez García FJ, et al. Mucinous adenocarcinoma of the prostate. Report of 3 cases and review of the literature. Arch Esp Urol. 1997;50:952-958.
126. Alguacil-Garcia A. Artifactual changes mimicking signet ring cell carcinoma in transurethral prostatectomy specimens. Am J Surg Pathol. 1986;10:795-800.
127. Teichman JM. Mucinous adenocarcinoma of the prostate: a report of a case of long-term survival. Urology. 1996;48:660.
128. Ben-Izhak O, Lichtig C. Signet-ring cell carcinoma of the prostate mimicking primary gastric carcinoma. J Clin Pathol. 1992;45:452-454.
129. Guerin D, Hasan N, Keen CE. Signet ring cell differentiation in adenocarcinoma of the prostate: a study of five cases. Histopathology. 1993;22:367-371.
130. Leong FJ, Leong AS, Swift J. Signet-ring carcinoma of the prostate. Pathol Res Pract. 1996;192:1232-1241.
131. Catton PA, Hartwick RW, Srigley Jr. Prostate cancer presenting with malignant ascites: signet-ring cell variant of prostatic adenocarcinoma. Urology. 1992;39:495-497.
132. Smith C, Feddersen RM, Dressler L, et al. Signet ring cell adenocarcinoma of prostate. Urology. 1994;43:397-400.
133. Torbenson M, Dhir R, Nangia A, et al. Prostatic carcinoma with signet ring cells: a clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol. 1998;11:552-559.
134. Yoshimura K, Fukui I, Ishikawa Y, et al. Locally-confined signet-ring cell carcinoma of the prostate: a case report of a long-term survivor. Int J Urol. 1996;3:406-407.
135. Giltman LI. Signet ring adenocarcinoma of the prostate. J Urol. 1981;126:134-135.
136. Curtis MW, Evans AJ, Srigley Jr. Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity. Mod Pathol. 2005;18:585-590.
137. Ortiz-Rey JA, Dos Santos JE, Rodríguez-Castilla M, et al. Mucinous urothelial-type adenocarcinoma of the prostate. Scand J Urol Nephrol. 2004;38:256-257.
138. Osunkoya AO, Epstein JI. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol. 2007;31:1323-1329.
139. Loo KT, Chan JK. Colloid adenocarcinoma of the urethra associated with mucosal in situ carcinoma. Arch Pathol Lab Med. 1992;116:976-977.
140. Silverman ML, Eyre RC, Zinman LA, et al. Mixed mucinous and papillary adenocarcinoma involving male urethra, probably originating in periurethral glands. Cancer. 1981;47:1398-1402.
141. Lee TK, Miller JS, Epstein JI. Rare histological patterns of prostatic ductal adenocarcinoma. Pathology. 2010;42: 319-324.
142. Nishimura K, Higashino M, Hara T, et al. Prostatic adenocarcinoma showing features of endometrioid and mucinous carcinomas: a case report. Hinyokika Kiyo. 1995; 41:805-807.
143. Van de Voorde W, Van Poppel H, et al. Mucin-secreting adenocarcinoma of the prostate with neuroendocrine differentiation and Paneth-like cells. Am J Surg Pathol. 1994; 18:200-207.
144. Weaver MG, Abdul-Karim FW, Srigley J, et al. Paneth celllike change of the prostate gland. A histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol. 1992;16:62-68.
145. Weaver MG, Abdul-Karim FW, Srigley Jr. Paneth cell-like change of the prostate. Arch Pathol Lab Med. 1992;116: 1101-1102.
146. Adlakha H, Bostwick DG. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol. 1994;25:135-139.
147. Tamas EF, Epstein JI. Prognostic significance of paneth celllike neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol. 2006;30:980-985.
148. Weaver MG, Abdul-Karim FW, Srigley Jr. Paneth cell-like change and small cell carcinoma of the prostate. Two divergent forms of prostatic neuroendocrine differentiation. Am J Surg Pathol. 1992;16:1013-1016.